Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background: Dementia with Lewy bodies (DLB) is a neurodegenerative disease where synaptic loss and reduced synaptic integrity are important neuropathological substrates. Neuronal Pentraxin 2(NPTX2) is a synaptic protein that drives the GABAergic inhibitory circuit. Our aim was to examine if NPTX2 cerebral spinal fluid (CSF) levels in DLB patients were altered and how these levels related to other synaptic protein levels and to cognitive function and decline. Methods: NPTX2, VGF, and α-synuclein levels were determined in CSF of cognitive healthy (n = 27), DLB (n = 48), and AD (n = 20) subjects. Multiple cognitive domains were tested, and data were compared using linear models. Results: Decreased NPTX2 levels were observed in DLB (median = 474) and AD (median = 453) compared to cognitive healthy subjects (median = 773). Strong correlations between NPTX2, VGF, and α-synuclein were observed dependent on diagnosis. Combined, these markers had a high differentiating power between DLB and cognitive healthy subjects (AUC = 0.944). Clinically, NPTX2 levels related to global cognitive function and cognitive decline in the visual spatial domain. Conclusion: NPTX2 CSF levels were reduced in DLB and closely correlated to decreased VGF and α-synuclein CSF levels. CSF NPTX2 levels in DLB related to decreased functioning in the visual spatial domain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This difference might result from PDD and DLB being Lewy body diseases characterized by α-synuclein accumulations, as indicated above [71, 72], while AD and FTD are caused by the accumulation of different proteins leading to distinct pathological mechanisms.”
The cited source says what the claim attributes to it.
In the citing paper
“NPTX2 CSF levels were lower in patients with DLB than in cognitive healthy controls (Boiten et al. 2020).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Boiten et al. 2020
In the citing paper
“We and others recently showed that decreased NPTX2 levels in DLB correlate with α-synuclein, confirming the possible interaction of α-synuclein aggregates that disturb pre-synaptic functioning when NPTX2 levels are decreased [71, 72].”
In the citing paper
“As for non-AD conditions, NPTX2 correlated with CSF levels of other synaptic proteins such as neurosecretory protein VGF and α-synuclein in DLB (Boiten et al. 2020).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Boiten et al. 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · cited 3×
“Deviations from relations between biomarkers observed in cognitive healthy subjects might be indicative of disease severity, as is done in AD with the AT(N) norms [13].”
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 1×
“Subjects were labelled as SCD when they presented to the memory clinic with subjective memory complains, yet had an unimpaired performance levels on the cognitive test, and criteria for mild cognitive impairment, AD, or other neurological or psychiatric disorders were not met [40].”
Wang, G., Cui, H.-L., & Huang, Y. (2018) · Neurology · doi:10.1212/wnl.0000000000004918 · Cited by 1,127 · cited 3×
“Cognitive decline in DLB differs from that in AD, since it shows a more pronounced effect on the visual spatial, attention, and executive function domains, in contrast to the predominant effects on the memory domain in AD [7–9].”
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Cell Biology and Pathophysiology of α-Synuclein
Burré, J., Sharma, M., & Südhof, T. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024091 · Cited by 579
Kramer, M. L., & Schulz-Schaeffer, W. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-06.2007 · Cited by 571
Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product narp.
O’Brien, R. J., Xu, D., Petralia, R. S., Steward, O., Huganir, R. L., & Worley, P. (1999) · Neuron · doi:10.1016/s0896-6273(00)80782-5 · Cited by 471 · cited 1×
“After exocytosis, this complex is able to mediate AMPA receptor, clustering post-synaptically at GABAergic interneurons [20].”
Self-citationOptimizing Patient Care and Research: The Amsterdam Dementia Cohort
van der Flier, W. M., Pijnenburg, Y. A. L., Prins, N., Lemstra, A. W., Bouwman, F. H., Teunissen, C. E., van Berckel, B. N. M., Stam, C. J., Barkhof, F., Visser, P. J., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132306 · Cited by 398 · cited 1×
“In this study, a total of 95 subjects were included from the Amsterdam dementia cohort [39], 27 with subjective cognitive decline (SCD), 48 with DLB, and 20 with AD.”
Self-citationNarp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons
Chang, M. C., Park, J. M., Pelkey, K. A., Grabenstatter, H. L., Xu, D., Linden, D. J., Sutula, T. P., McBain, C. J., & Worley, P. F. (2010) · Nature Neuroscience · doi:10.1038/nn.2621 · Cited by 316
Self-citation
Cited by
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112
Brockmann, K., Quadalti, C., Lerche, S., Rossi, M., Wurster, I., Baiardi, S., Röeben, B., Mammana, A., Zimmermann, M., Hauser, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01276-6 · Cited by 138
Nilsson, J., Binette, A. P., Palmqvist, S., Brum, W. S., Janelidze, S., Ashton, N. J., Spotorno, N., Stomrud, E., Gobom, J., Zetterberg, H., et al. (2024) · Brain · doi:10.1093/brain/awae032 · Cited by 92
“…lower CSF concentrations of the pentraxins in AD 38,42,53-57 as well as in other neurodegenerative diseases such as atypical parkinsonism, 39 DLB 38,58,59 and FTLD. 38,59,60 In a previous study, lower levels of NPTX2 were also observed in PD compared with controls; the re-sults were not replicated…”
ResultNilsson, J., Cousins, K. A. Q., Gobom, J., Portelius, E., Chen‐Plotkin, A. S., Shaw, L. M. J., Grossman, M., Irwin, D. J., Trojanowski, J. Q., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12809 · Cited by 65
Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer’s Disease
Bousiges, O., & Blanc, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126371 · Cited by 68
Nilsson, J., Constantinescu, J., Nellgård, B., Jakobsson, P., Brum, W. S., Gobom, J., Forsgren, L., Dalla, K., Constantinescu, R., Zetterberg, H., et al. (2022) · Movement Disorders · doi:10.1002/mds.29287 · Cited by 64
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
Vijiaratnam, N., & Foltynie, T. (2023) · Brain · doi:10.1093/brain/awad265 · Cited by 59
“111,263 Similarly, combining CSF Ng, NPTX2, total α -syn and age 273 or CNTN-1, total α -syn, total tau, phosphorylated tau and A β 1-42261 ) can also improve diagnostic distinction.”
BackgroundSoldan, A., Oh, S., Ryu, T., Pettigrew, C. A., Zhu, Y., Moghekar, A., Xiao, M., Pontone, G. M., Albert, M., Na, C. H., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26725 · Cited by 51
“Additional investigations are also needed to determine if NPTX2 improves prediction of MCI independent of other comorbid pathologies that also affect synapses (eg, cerebrovascular disease 37 and alpha-synuclein 38 ).”
Self-citationBolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220318 · Cited by 36
“This difference might result from PDD and DLB being Lewy body diseases characterized by synuclein accumulations, as indicated above [71, 72], while AD and FTD are caused by the accumulation of different proteins leading to distinct pathological mechanisms.”
Self-citationBergström, S., Öijerstedt, L., Remnestål, J., Olofsson, J., Ullgren, A., Seelaar, H., Swieten, J. C. V., Synofzik, M., Sánchez‐Valle, R., Moreno, F., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00499-4 · Cited by 39
“VGF is related to synaptic function, and a strong correlation (rho = 0.70) between VGF and NPTX2 levels was previously observed in patients with DLB and AD by Boiten et al. 2020 [51], which is in concordance with the strong correlation (rho = 0.83) we observed in this FTD cohort.”
ResultInfluentialVGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders
Wang, Y., Qin, X., Han, Y. J., & Li, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113099 · Cited by 33
Brain-Biomarker Changes in Body Fluids of Patients with Parkinson’s Disease
Cocco, C., Manai, A. L., Manca, E., & Noli, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310932 · Cited by 20
Self-citationSaloner, R., Staffaroni, A., Dammer, E., Johnson, E. C. B., Paolillo, E., Wise, A. B., Heuer, H., Forsberg, L., Lago, A., Webb, J. D., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4103685/v1 · Cited by 18
“CSF NPTX2, previously shown to decrease in symptomatic FTLD and other neurodegenerative diseases 45–47 , exhibited the strongest association with cognitive decline out of any individual protein.”
Bartl, M., Nilsson, J., Dakna, M., Weber, S. K., Schade, S., Xylaki, M., Gomes, B. F., Ernst, M. S., Muntean, M., Sixel‐Döring, F., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00714-1 · Cited by 19
“Lower levels of the secreted glycoproteins NPTX1 and NPTX2 are related to more severe non-motor PD symptoms and cognitive de fi cits, measured by MDS-UPDRSpart I, supporting previous fi ndingsinPD 33,36,37 .”
Mravinacová, S., Bergström, S., Olofsson, J., José, N. G. D. S., Anderl‐Straub, S., Diehl‐Schmid, J., Fassbender, K. C., Fließbach, K., Jahn, H., Kornhuber, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-83281-y · Cited by 15
α-synuclein as an emerging pathophysiological biomarker of Alzheimer’s disease
Beatino, M. F., Luca, C. D., Campese, N., Belli, E., Piccarducci, R., Giampietri, L., Martini, C., Perugi, G., Siciliano, G., Ceravolo, R., et al. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2068952 · Cited by 13
“) CU [68,71] CU (PLS-DA) [76] PDD [71] FTLD° [68] LBD [68] ALS, ALS° [68] CJD (PLS-DA) [76] PSP [68]) SMC [77] CU [72] PD [72] FTD [68] VD (PLS-DA)[76] DLB [72,77] LRP°[68]”
BackgroundInfluentialHuman neural networks with sparse TDP-43 pathology reveal NPTX2 misregulation in ALS/FTLDPreprint
Hruska-Plochan, M., Betz, K. M., Ronchi, S., Wiersma, V. I., Maniecka, Z., Hock, E., Laferrière, F., Sahadevan, S., Hoop, V., Delvendahl, I., et al. (2021) · bioRxiv · doi:10.1101/2021.12.08.471089 · Cited by 11
Piel, J. H. A., Bargemann, L., Leypoldt, F., Wandinger, K., & Dargvainiene, J. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1356575 · Cited by 12
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 13
González, A. C., Goossens, J., Vera-Campuzano, E., Sala, I., Sánchez‐Saudinós, M. B., Rodríguez‐Baz, Í., Lidón, L., Perlaza, D., Bejanin, A., Haapasalo, A., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01685-y · Cited by 11
Biofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 11
Fluid markers of synapse degeneration in synucleinopathies
Cervantes González, A., & Belbin, O. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02467-8 · Cited by 7
Anderson, C. L., Gross, A. L., Pettigrew, C. A., Vazquez, J. P., Moghekar, A., Oh, S., Na, C. H., Albert, M., Worley, P. F., & Soldan, A. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.09.002 · Cited by 9
Self-citationSaloner, R., Staffaroni, A. M., Dammer, E. B., Johnson, E. C. B., Paolillo, E. W., Wise, A. B., Heuer, H. W., Forsberg, L. K., Lario‐Lago, A., Webb, J. D., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00878-2 · Cited by 24
“CSF NPTX2, previously shown to decrease in symptomatic FTLD and other neurodegenerative diseases 45–47 , exhibited the strongest association with cognitive decline out of any individual protein.”
Patel, M., Zhang, Y., Xiao, M.-F., Worley, P. F., & Moghekar, A. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.98212 · Cited by 9
“In cerebrospinal fluid (CSF), reduced levels of NPTX2 have been observed in AD [3], genetic frontotemporal dementia [4], and dementia with Lewy bodies [5], leading to its promising potential use as a biomarker in these disorders.”
BackgroundSelf-citationCSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer’s Dementia Spectrum
Behzad, M., Zirak, N., Madani, G. H., Baidoo, L., Rezaei, A., Karbasi, S., Sadeghi, M. R., Shafie, M., Mayeli, M., & Initiative, A. D. N. (2023) · International Journal of Alzheimer s Disease · doi:10.1155/2023/5336273 · Cited by 8
“Although the mechanism behind the decrease in the level of VGF in CFS of AD patients is not clear yet [49], a lower level of the VGF protein gene can be influenced by a decrease in the level of NPTX2 [50].”
BackgroundInfluentialDevelopment and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome
Sauer, M., Gomes, B. F., Shahrouki, P., Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Camporesi, E., Belbin, O., Alcolea, D. A., Kumar, A., Sharma, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70241 · Cited by 8
NERP-1 modifications in amyotrophic lateral sclerosis
Noli, B., Borghero, G., Mascia, M. G., Hkir, M., Puligheddu, M., & Cocco, C. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.102780 · Cited by 4
Self-citationCSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson's disease
Hauer, K. O., Hall, S., Nahimi, A., Strandberg, O. T., Ohlsson, T. G., Jögi, J., Stomrud, E., Janelidze, S., Hansson, O., & Smith, R. A. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.108005 · Cited by 3
van Amerongen, S., Das, S., Kamps, S., Goossens, J., Bongers, B., Pijnenburg, Y. A. L., Vanmechelen, E., Vijverberg, E. G. B., Teunissen, C. E., & Verberk, I. M. W. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.06.001 · Cited by 2
“NPTX2 is a protein that plays a crucial role in synaptic plasticity and is linked to excitatory synapses associated with parvalbumin interneurons (Boiten et al., 2020).”
Self-citationGomes, B. F., Sauer, M., Montoliu‐Gaya, L., Franquesa‐Mullerat, M., Bejanin, A., Alcolea, D. A., Lleó, A., Illán‐Gala, I., Fortea, J., Blennow, K., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70391 · Cited by 2
VGF AQEE- and GGEE-peptides differentiate between dementia types
Noli, B., Muqaku, B., Gouda, M., Manai, A., Nagl, M., Anderl‐Straub, S., Werner, L., Otto, M., Teunissen, C. E., Oeckl, P., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13441-1
“…previous studies, we demonstrated that DLB patients could be reliably distinguished from both AD patients and controls by a significant decrease in the levels of AQEE-10 measured using selective mass spectrometry (SMR) and GGEE peptides (quantified using enzyme-linked immunosorbent assay) [7–9].”
Self-citationBoiten, W. A., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G., Lemstra, A., & Teunissen, C. (2022) · Cells · doi:10.3390/cells11040652
Self-citation
Metadata
- Authors
- Boiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C.
- Affiliations
- Amsterdam University Medical Centers (NL)
- Johns Hopkins University (US)
- University of Cagliari (IT)
- Corresponding author
- Boiten, Walter
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-12-29
- Volume
- 10
- Issue
- 1
- Pages
- 38
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7824459
- OpenAlex
- W3117487831
- Cited by
- 42
- References
- 42
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 7 · 2023: 4 · 2022: 9 · 2021: 10
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-12-29)
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- ZonMw (733050509, 733050102)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- dementia with Lewy bodies, NPTX2, alpha-synuclein, VGF, cerebrospinal fluid biomarkers, synaptic loss, Alzheimer's disease, cognitive decline, visuospatial ability, GABAergic inhibition
- MeSH terms
- Pentraxins, Aged, C-Reactive Protein, Female, Humans, Male, Middle Aged, Nerve Growth Factors, Nerve Tissue Proteins, Cohort Studies, Biomarkers, Case-Control Studies, Lewy Body Disease, alpha-Synuclein, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.